High-efficiency antioxidant ROS-responsive thermosensitive hydrogel se-PEG-PPG encapsulated Fenofibrate for the treatment of corneal neovascularization
Kai Fan, Dejun Yang, Xinyi Zhu, Lan Zheng, Yi Han, Jingwei Lin, Zixun Xiang, Yafei Guo, Keyue Tao, Juntong Li, Jia Qu, Yunlong Wu, Huaqiong Li, Cheng Li
{"title":"High-efficiency antioxidant ROS-responsive thermosensitive hydrogel se-PEG-PPG encapsulated Fenofibrate for the treatment of corneal neovascularization","authors":"Kai Fan, Dejun Yang, Xinyi Zhu, Lan Zheng, Yi Han, Jingwei Lin, Zixun Xiang, Yafei Guo, Keyue Tao, Juntong Li, Jia Qu, Yunlong Wu, Huaqiong Li, Cheng Li","doi":"10.1016/j.jconrel.2025.113650","DOIUrl":null,"url":null,"abstract":"Corneal neovascularization (CNV) has become one of the common blinding ocular diseases recognized worldwide, affecting millions of people every year. Numerous studies have shown that oxidative stress and inflammation are important factors for the occurrence and development of CNV. In the present study, we established an antioxidant and reactive oxygen species (ROS) responsive thermosensitive hydrogel for long-acting drug delivery, combining with the loaded anti-angiogenic drug to the therapy for CNV. Se-PEG-PPG (SePEP) could in-situ gelling on the ocular surface temperature and cover the ocular surface. The hydrophobic interaction between the selenium ether segment and ocular mucin will further increase its adhesion on the ocular surface, which is conducive to drug Fenofibrate (Feno) retention and sustained release on the ocular surface. SePEP also played a role in reducing intracellular oxidative stress and oxidative responsive sustained release drug due to its selenium ether groups that scavenge ROS. Finally, the combined anti-oxidation, anti-inflammation, and anti-angiogenesis therapeutic effect of Feno@Se-PEG-PPG (SePEP-Feno) eye drops were demonstrated in a corneal neovascularization animal model. In conclusion, the multifunctional delivery system provided a promising method for the treatment of CNV and various ROS-related ocular diseases.","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"62 1","pages":""},"PeriodicalIF":10.5000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jconrel.2025.113650","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Corneal neovascularization (CNV) has become one of the common blinding ocular diseases recognized worldwide, affecting millions of people every year. Numerous studies have shown that oxidative stress and inflammation are important factors for the occurrence and development of CNV. In the present study, we established an antioxidant and reactive oxygen species (ROS) responsive thermosensitive hydrogel for long-acting drug delivery, combining with the loaded anti-angiogenic drug to the therapy for CNV. Se-PEG-PPG (SePEP) could in-situ gelling on the ocular surface temperature and cover the ocular surface. The hydrophobic interaction between the selenium ether segment and ocular mucin will further increase its adhesion on the ocular surface, which is conducive to drug Fenofibrate (Feno) retention and sustained release on the ocular surface. SePEP also played a role in reducing intracellular oxidative stress and oxidative responsive sustained release drug due to its selenium ether groups that scavenge ROS. Finally, the combined anti-oxidation, anti-inflammation, and anti-angiogenesis therapeutic effect of Feno@Se-PEG-PPG (SePEP-Feno) eye drops were demonstrated in a corneal neovascularization animal model. In conclusion, the multifunctional delivery system provided a promising method for the treatment of CNV and various ROS-related ocular diseases.
期刊介绍:
The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System.
Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries.
Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.